{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:16:14Z","timestamp":1768835774884,"version":"3.49.0"},"reference-count":38,"publisher":"Portland Press Ltd.","issue":"6","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"abstract":"<jats:p>The NCLs (neuronal ceroid lipofuscinoses) are the most common inherited paediatric neurodegenerative disorder. Although genetically distinct, NCLs can be broadly divided into two categories: one in which the mutation results in a defect in a transmembrane protein, and the other where the defect lies in a soluble lysosomal enzyme. A number of therapeutic approaches are applicable to the soluble lysosomal forms of NCL based on the phenomenon of cross-correction, whereby the ubiquitously expressed mannose 6-phosphate\/IGF (insulin-like growth factor) II receptor provides an avenue for endocytosis, trafficking and lysosomal processing of extracellularly delivered enzyme. The present review discusses therapeutic utilization of cross-correction by enzyme-replacement therapy, gene therapy and stem cell therapy for the NCLs, along with an overview of the recent progress in translating these treatments into the clinic.<\/jats:p>","DOI":"10.1042\/bst0381484","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T15:07:34Z","timestamp":1291216054000},"page":"1484-1488","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis"],"prefix":"10.1042","volume":"38","author":[{"given":"Andrew\u00a0M.S.","family":"Wong","sequence":"first","affiliation":[{"name":"Pediatric Storage Disorders Laboratory, Department of Neuroscience and Centre for the Cellular Basis of Behaviour, MRC Centre for Neurodegeneration Research, James Black Centre, Institute of Psychiatry, King's College London, 125 Coldharbour Lane, London SE5 9NU, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahad\u00a0A.","family":"Rahim","sequence":"additional","affiliation":[{"name":"Gene Transfer Technology Group, Institute for Women's Health, 86\u201396 Chenies Mews, University College London, London WC1E 6HX, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon\u00a0N.","family":"Waddington","sequence":"additional","affiliation":[{"name":"Gene Transfer Technology Group, Institute for Women's Health, 86\u201396 Chenies Mews, University College London, London WC1E 6HX, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan\u00a0D.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Pediatric Storage Disorders Laboratory, Department of Neuroscience and Centre for the Cellular Basis of Behaviour, MRC Centre for Neurodegeneration Research, James Black Centre, Institute of Psychiatry, King's College London, 125 Coldharbour Lane, London SE5 9NU, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2010,11,24]]},"reference":[{"key":"2021111909511964900_B1","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1042\/BST0381448","article-title":"The neuronal ceroid lipofuscinoses: the same, but different?","volume":"38","author":"Cooper","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"2021111909511964900_B2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/B978-0-12-374105-9.00492-5","article-title":"Neuronal ceroid lipofuscinosis","volume-title":"Encyclopedia of Movement Disorders, vol. 2","author":"Cooper","year":"2010"},{"key":"2021111909511964900_B3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.169.3941.141","article-title":"Inborn errors of mucopolysaccharide metabolism","volume":"169","author":"Neufeld","year":"1970","journal-title":"Science"},{"key":"2021111909511964900_B4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage disorders","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"2021111909511964900_B5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V78.5.1183.1183","article-title":"Enzyme replacement therapy for Gaucher disease","volume":"78","author":"Beutler","year":"1991","journal-title":"Blood"},{"key":"2021111909511964900_B6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"2021111909511964900_B7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021111909511964900_B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021111909511964900_B9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/bj3570049","article-title":"Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis","volume":"357","author":"Lin","year":"2001","journal-title":"Biochem. J."},{"key":"2021111909511964900_B10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ymgme.2008.01.014","article-title":"Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis","volume":"94","author":"Sleat","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"2021111909511964900_B11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","article-title":"Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Chang","year":"2008","journal-title":"Mol. Ther."},{"key":"2021111909511964900_B12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","article-title":"Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Griffey","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"2021111909511964900_B13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymthe.2005.04.018","article-title":"AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis","volume":"12","author":"Griffey","year":"2005","journal-title":"Mol. Ther."},{"key":"2021111909511964900_B14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ymthe.2005.11.008","article-title":"CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis","volume":"13","author":"Griffey","year":"2006","journal-title":"Mol. Ther."},{"key":"2021111909511964900_B15","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.gt.3302549","article-title":"AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL","volume":"12","author":"Sondhi","year":"2005","journal-title":"Gene Ther."},{"key":"2021111909511964900_B16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1523\/JNEUROSCI.2676-05.2006","article-title":"Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis","volume":"26","author":"Passini","year":"2006","journal-title":"J. Neurosci."},{"key":"2021111909511964900_B17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1089\/hum.2005.16.1484","article-title":"Safety of direct administration of AAV2CUhCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates","volume":"16","author":"Hackett","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"2021111909511964900_B18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/hum.2004.15.1131","article-title":"Clinical protocol: administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis","volume":"15","author":"Crystal","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"2021111909511964900_B19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"2021111909511964900_B20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol. Ther."},{"key":"2021111909511964900_B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2008.04.022","article-title":"Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis","volume":"213","author":"Sondhi","year":"2008","journal-title":"Exp. Neurol."},{"key":"2021111909511964900_B22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1750-3639.2006.00002.x","article-title":"Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis","volume":"16","author":"Kay","year":"2006","journal-title":"Brain Pathol."},{"key":"2021111909511964900_B23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1042\/BST0381489","article-title":"In utero gene transfer to the mouse nervous system","volume":"38","author":"Rahim","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"2021111909511964900_B24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/gt.2008.186","article-title":"Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors","volume":"16","author":"Rahim","year":"2009","journal-title":"Gene Ther."},{"key":"2021111909511964900_B25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"2021111909511964900_B26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"2021111909511964900_B27","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/stem.163","article-title":"Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease","volume":"27","author":"Jeyakumar","year":"2009","journal-title":"Stem Cells"},{"key":"2021111909511964900_B28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/stem.401","article-title":"Bone marrow-derived mesenchymal stem cells prevent the loss of Niemann\u2013Pick type\u00a0C mouse Purkinje neurons by correcting sphingolipid metabolism and increasing sphingosine1-phosphate","volume":"28","author":"Lee","year":"2010","journal-title":"Stem Cells"},{"key":"2021111909511964900_B29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.stem.2009.05.022","article-title":"Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis","volume":"5","author":"Tamaki","year":"2009","journal-title":"Cell Stem Cell"},{"key":"2021111909511964900_B30","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.STR.32.4.1012","article-title":"Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells","volume":"32","author":"Veizovic","year":"2001","journal-title":"Stroke"},{"key":"2021111909511964900_B31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainres.2005.09.049","article-title":"Neural stem cell grafts reduce the extent of neuronal damage in a mouse model of global ischaemia","volume":"1063","author":"Wong","year":"2005","journal-title":"Brain Res."},{"key":"2021111909511964900_B32","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.neuroscience.2006.01.025","article-title":"Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease","volume":"139","author":"Roberts","year":"2006","journal-title":"Neuroscience."},{"key":"2021111909511964900_B33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2006.09.001","article-title":"Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis","volume":"25","author":"Kielar","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"2021111909511964900_B34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/nen.0b013e31815f3899","article-title":"Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis","volume":"67","author":"Partanen","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2021111909511964900_B35","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111909511964900_B36","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"2021111909511964900_B37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ana.21284","article-title":"Chemical chaperone therapy: clinical effect in murine GM1-gangliosidosis","volume":"62","author":"Suzuki","year":"2007","journal-title":"Ann. Neurol."},{"key":"2021111909511964900_B38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2010.03.137","article-title":"Palmitoyl protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease","volume":"395","author":"Dawson","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/38\/6\/1484\/549793\/bst0381484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/38\/6\/1484\/549793\/bst0381484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T09:51:56Z","timestamp":1637315516000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/38\/6\/1484\/90301\/Current-therapies-for-the-soluble-lysosomal-forms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,24]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,11,24]]},"published-print":{"date-parts":[[2010,12,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bst0381484","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,24]]}}}